1. A. Amatu, A. SartoreBianchi, S. Siena, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, ESMOOpen1 (2016) e000023.
2. Larotrectinib for paediatric solid tumours harbouring NTRK genefusions:phase-1results from multicentre, open-label, phase1/2study;Laetsch;LancetOncol.,2018
3. Identification of NTRK fusions in pediatricmesenchymaltumors;Pavlick;Pediatr. Blood Cancer,2017
4. A. Drilon, T.W. Laetsch, S. Kummar, S.G. DuBois, U.N. Lassen, G.D. Demetri, M. Nathenson, R.C. Doebele, A.F. Farago, A.S. Pappo, B. Turpin, A. Dowlati, Deiry, C. Baik, J. Deeken, V. Boni, R. Nagasubramanian, M. Taylor, E.R. Rudzinski, F. MericBernstam, D.P.S. Sohal, P.C. Ma, L.E. Raez, J.F. Hechtman, R. Benayed, M. Ladanyi, B.B. Tuch, K. Ebata, S. Cruickshank, N.C. Ku, M.C. Cox, D.S. Hawkins, D.S. Hong, D.M. Hyman, Efficacy of larotrectinibin TRK fusion positive cancers in adults and children,N.Engl.J.Med.378(2018)731–739.
5. Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry;Sparidans;J. Chromatography B,2018